European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Keywords: Haemophilia, Guidelines, Inhibitors, Factor VIII, Factor IX, Bypassing agents, Emicizumab, Immune tolerance

Saved in:

Bibliographic Details
Published in:	Orphanet journal of rare diseases Vol. 15; no. 1; pp. 1 - 219
Main Authors:	Hermans, C, Giangrande, P. L. F, O'Mahony, B, de Kleijn, P, Bedford, M, Batorova, A, BlatnÃ½, J, Jansone, K, Astermark, J, Crato, M, d'Oiron, R, Dougall, A, Fijnvandraat, K, Granhaug, S, Jiménez-Yuste, V, JokiÄ, M, Lobet, S, Nolan, B, Peyvandi, F, Ryan, A
Format:	Journal Article
Language:	English
Published:	London BioMed Central Ltd 24-08-2020 BioMed Central BMC
Subjects:	Antibodies Bispecific antibodies Blood coagulation factors Bypassing agents Care and treatment Clinical trials Clotting Coagulation factors Collaboration Consortia Factor IX Factor VIII Guidelines Haemophilia Hemophilia Inhibitors Letter to the Editor Medical research Patients Pharmacovigilance Prophylaxis Prothrombin Rare diseases Risk factors Surgery Tranexamic acid
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Keywords: Haemophilia, Guidelines, Inhibitors, Factor VIII, Factor IX, Bypassing agents, Emicizumab, Immune tolerance
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	1750-1172 1750-1172
DOI:	10.1186/s13023-020-01511-8